IP Library › Granted Patent US 12,492,244
Granted Patent B2
US 12,492,244 · App. 17/290,154 · Granted Dec 9, 2025

Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof

Inventors: Bongcheol Kim (Seongnam-si, KR); Wonkyum Kim (Seoul, KR); Dong Sik Kim (Seoul, KR); Jae-Keun Lee (Seoul, KR); Jeongwon Yoon (Sejong-si, KR); Junho Chung (Seongnam-si, KR); Junyeong Jin (Gwachun-si, KR)
Assignee: NEURACLE SCIENCE CO., LTD.
C07K16/24C07K2317/24C07K2317/34C07K2317/54C07K2317/55C07K2317/56C07K2317/622C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,492,244
App. No.
17/290,154
Granted
Dec 9, 2025
Kind
B2
Abstract

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In some embodiments, antibodies are de-immunized to reduce immunogenicity in a human subject. In certain embodiments, antibodies have undergone affinity maturation. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

Claims (19)

1 . An isolated antibody, or antigen binding portion thereof, which specifically binds a human family with sequence similarity 19, member AS (FAM19A5) protein (“anti-FAM19A5 antibody”), comprising a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3,

wherein (i) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14; (ii) the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15; (iii) the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 7; (iv) the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 21; (v) the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24; and (vi) the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 23.

2 . The anti-FAM19A5 antibody of claim 1 , comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence which is at least about 80% identical to the amino acid sequence set forth in SEQ ID NO: 34; and/or wherein the VL comprises an amino acid sequence which is at least about 80% identical to the amino acid sequence set forth in SEQ ID NO: 40.

3 . The anti-FAM19A5 antibody of claim 1 , which comprises a Fab, a Fab′, a F(ab′)2, a Fv, or a single chain Fv (scFv).

4 . The anti-FAM19A5 antibody of claim 1 , which is a chimeric antibody or a humanized antibody.

5 . A bispecific molecule comprising the anti-FAM19A5 antibody of claim 1 .

6 . An immunoconjugate comprising the anti-FAM19A5 antibody of claim 1 linked to a therapeutic agent, wherein the therapeutic agent modulates onset of gliosis and/or reactive astrogliosis and/or treat a degenerative brain disorder, central nervous system damage, or neuropathic pain.

7 . A composition comprising the anti-FAM19A5 antibody of claim 1 and a carrier.

8 . A composition comprising the anti-FAM19A5 antibody of claim 2 and a carrier.

9 . An immunoconjugate comprising the anti-FAM19A5 antibody of claim 2 linked to a therapeutic agent, wherein the therapeutic agent modulates onset of gliosis and/or reactive astrogliosis and/or treat a degenerative brain disorder, central nervous system damage, or neuropathic pain.

10 . The anti-FAM19A5 antibody of claim 2 , wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 34 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 40.

11 . The anti-FAM19A5 antibody of claim 2 , which is a chimeric antibody or a humanized antibody.

12 . The anti-FAM19A5 antibody of claim 2 , which comprises a Fab, a Fab′, a F(ab′)2, a Fv, or a single chain Fv (scFv).

13 . A bispecific molecule comprising the anti-FAM19A5 antibody of claim 2 .

14 . An immunoconjugate comprising the anti-FAM19A5 antibody of claim 10 linked to a therapeutic agent, wherein the therapeutic agent modulates onset of gliosis and/or reactive astrogliosis and/or treat a degenerative brain disorder, central nervous system damage, or neuropathic pain.

15 . A composition comprising the anti-FAM19A5 antibody of claim 10 and a carrier.

16 . The anti-FAM19A5 antibody of claim 10 , which is a chimeric antibody or a humanized antibody.

17 . The anti-FAM19A5 antibody of claim 10 , which comprises a Fab, a Fab′, a F(ab′)2, a Fv, or a single chain Fv (scFv).

18 . A bispecific molecule comprising the anti-FAM19A5 antibody of claim 10 .

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2025
From: KIM, BONGCHEOL; KIM, WONKYUM; KIM, DONG SIK; LEE, JAE-KEUN
To: NEURACLE SCIENCE CO., LTD.
Reel/Frame 072497/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2025
From: YOON, JEONGWON
To: NEURACLE SCIENCE CO., LTD.
Reel/Frame 072497/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2025
From: KIM, BONGCHEOL; KIM, WONKYUM; KIM, DONG SIK; LEE, JAE-KEUN; YOON, JEONGWON
To: NEURACLE SCIENCE CO., LTD.
Reel/Frame 072497/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2025
From: CHUNG, JUNHO; JIN, JUNYEONG
To: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Reel/Frame 072497/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2025
From: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
To: NEURACLE SCIENCE CO., LTD.
Reel/Frame 072497/0432 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2025
From: CHUNG, JUNHO; JIN, JUNYEONG
To: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Reel/Frame 073027/0942 →
Continuity (3)
Provisional Application 62787711 · Jan 2, 2019
Provisional Application 62838190 · Apr 24, 2019
Related Publication 20220144932A1 · May 12, 2022
References Cited (289)
US 4044126A · Cook et al. · 1977 [cited by applicant]
US 4364923A · Cook et al. · 1982 [cited by applicant]
US 4414209A · Cook et al. · 1983 [cited by applicant]
US 4444887A · Hoffmann · 1984 [cited by applicant]
US 4716111A · Osband et al. · 1987 [cited by applicant]
US 4816397A · Boss et al. · 1989 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4881175A · Ladner · 1989 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5013653A · Huston et al. · 1991 [cited by applicant]
US 5091513A · Huston et al. · 1992 [cited by applicant]
US 5122464A · Wilson et al. · 1992 [cited by applicant]
US 5132405A · Huston et al. · 1992 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5258498A · Huston et al. · 1993 [cited by applicant]
US 5260203A · Ladner et al. · 1993 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5413923A · Kucherlapati et al. · 1995 [cited by applicant]
US 5427908A · Dower et al. · 1995 [cited by applicant]
US 5455030A · Ladner et al. · 1995 [cited by applicant]
US 5476786A · Huston et al. · 1995 [cited by applicant]
US 5482858A · Huston et al. · 1996 [cited by applicant]
US 5516637A · Huang et al. · 1996 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5580717A · Dower et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5658727A · Barbas et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5693780A · Newman et al. · 1997 [cited by applicant]
US 5698426A · Huse · 1997 [cited by applicant]
US 5709874A · Hanson et al. · 1998 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5750753A · Kimae et al. · 1998 [cited by applicant]
US 5759542A · Gurewich · 1998 [cited by applicant]
US 5766886A · Studnicka et al. · 1998 [cited by applicant]
US 5780225A · Wigler et al. · 1998 [cited by applicant]
US 5807715A · Morrison et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5821047A · Garrard et al. · 1998 [cited by applicant]
US 5837242A · Holliger et al. · 1998 [cited by applicant]
US 5840674A · Yatvin et al. · 1998 [cited by applicant]
US 5860957A · Jacobsen et al. · 1999 [cited by applicant]
US 5869620A · Whitlow et al. · 1999 [cited by applicant]
US 5885793A · Griffiths et al. · 1999 [cited by applicant]
US 5900252A · Calanchi et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5948433A · Burton et al. · 1999 [cited by applicant]
US 5969108A · Mccafferty et al. · 1999 [cited by applicant]
US 5972366A · Haynes et al. · 1999 [cited by applicant]
US 5983134A · Ostrow · 1999 [cited by applicant]
US 5985307A · Hanson et al. · 1999 [cited by applicant]
US 5985317A · Venkateshwaran et al. · 1999 [cited by applicant]
US 5989830A · Davis et al. · 1999 [cited by applicant]
US 6004534A · Langer et al. · 1999 [cited by applicant]
US 6005079A · Casterman et al. · 1999 [cited by applicant]
US 6010715A · Wick et al. · 2000 [cited by applicant]
US 6024975A · D Angelo et al. · 2000 [cited by applicant]
US 6039975A · Shah et al. · 2000 [cited by applicant]
US 6048736A · Kosak · 2000 [cited by applicant]
US 6060082A · Chen et al. · 2000 [cited by applicant]
US 6071495A · Unger et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6120751A · Unger · 2000 [cited by applicant]
US 6131570A · Schuster et al. · 2000 [cited by applicant]
US 6132992A · Ledbetter et al. · 2000 [cited by applicant]
US 6139865A · Friend et al. · 2000 [cited by applicant]
US 6150184A · Evans et al. · 2000 [cited by applicant]
US 6167301A · Flower et al. · 2000 [cited by applicant]
US 6253872B1 · Neumann · 2001 [cited by applicant]
US 6256533B1 · Yuzhakov et al. · 2001 [cited by applicant]
US 6261595B1 · Stanley et al. · 2001 [cited by applicant]
US 6267983B1 · Fujii et al. · 2001 [cited by applicant]
US 6271359B1 · Norris et al. · 2001 [cited by applicant]
US 6274552B1 · Tamarkin et al. · 2001 [cited by applicant]
US 6316652B1 · Steliou · 2001 [cited by applicant]
US 6331415B1 · Cabilly et al. · 2001 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7951917B1 · Arathoon et al. · 2011 [cited by applicant]
US 8227577B2 · Klein et al. · 2012 [cited by applicant]
US 8586713B2 · Davis et al. · 2013 [cited by applicant]
US 20040014194A1 · Beyer et al. · 2004 [cited by applicant]
US 20050042664A1 · Wu et al. · 2005 [cited by applicant]
US 20120100140A1 · Reyes et al. · 2012 [cited by applicant]
US 20150118230A1 · Seong et al. · 2015 [cited by applicant]
US 20150118320A1 · Inokunchi et al. · 2015 [cited by applicant]
US 20210070849A1 · Kim · 2021 [cited by examiner]
US 20210388382A1 · Kim · 2021 [cited by examiner]
EP 0239400A2 · 1987 [cited by applicant]
EP 0519596A1 · 1992 [cited by applicant]
EP 0592106A1 · 1994 [cited by applicant]
EP 1074563A1 · 2001 [cited by applicant]
KR 20160101786A · 2016 [cited by applicant]
WO WO8605807A1 · 1986 [cited by applicant]
WO WO8901036A1 · 1989 [cited by applicant]
WO WO9002809A1 · 1990 [cited by applicant]
WO WO9109967A1 · 1991 [cited by applicant]
WO WO9110737A1 · 1991 [cited by applicant]
WO WO9110741A1 · 1991 [cited by applicant]
WO WO9201047A1 · 1992 [cited by applicant]
WO WO9218619A1 · 1992 [cited by applicant]
WO WO9222324A1 · 1992 [cited by applicant]
WO WO9311236A1 · 1993 [cited by applicant]
WO WO9317105A1 · 1993 [cited by applicant]
WO WO9404678A1 · 1994 [cited by applicant]
WO WO9425591A1 · 1994 [cited by applicant]
WO WO9515982A2 · 1995 [cited by applicant]
WO WO9517886A1 · 1995 [cited by applicant]
WO WO9520401A1 · 1995 [cited by applicant]
WO WO9633735A1 · 1996 [cited by applicant]
WO WO9634096A1 · 1996 [cited by applicant]
WO WO9712622A1 · 1997 [cited by applicant]
WO WO9713844A1 · 1997 [cited by applicant]
WO WO9816654A1 · 1998 [cited by applicant]
WO WO9817815A1 · 1998 [cited by applicant]
WO WO9817816A1 · 1998 [cited by applicant]
WO WO9818934A1 · 1998 [cited by applicant]
WO WO9824893A2 · 1998 [cited by applicant]
WO WO9846645A2 · 1998 [cited by applicant]
WO WO9850433A2 · 1998 [cited by applicant]
WO WO9852976A1 · 1998 [cited by applicant]
WO WO9931251A1 · 1999 [cited by applicant]
WO WO0034317A2 · 2000 [cited by applicant]
WO WO0144301A1 · 2001 [cited by applicant]
WO WO02092780A2 · 2002 [cited by applicant]
WO WO03074679A2 · 2003 [cited by applicant]
WO WO2009059278A1 · 2009 [cited by applicant]
WO WO2018083538A1 · 2018 [cited by applicant]
WO WO2019003159A1 · 2019 [cited by applicant]
WO WO2019003162A1 · 2019 [cited by applicant]
WO WO2019003164A1 · 2019 [cited by applicant]
WO WO2019003165A1 · 2019 [cited by applicant]
WO WO2019207513 · 2019 [cited by examiner]
WO WO2020141452A1 · 2020 [cited by applicant]
Aarts, L.H., et al., “The role of the neural growth associated protein B-50/GAP-43 in morphogenesis,” Adv Exp Med Biol 446:85-106, Springer, United States (1998). [cited by applicant]
Ames, R.S., et al., “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins,” J Immunol Methods 184(2):177-186, Elsevier, Netherlands (Aug. 1995). [cited by applicant]
An, Z., et al., “IgG2m4, an engineered antibody isotype with reduced Fc function,” Mabs 1(6):572-579, Landes Bioscience, United States (Nov.-Dec. 2009). [cited by applicant]
Baca, M., et al., “Antibody humanization using monovalent phage display,” J Biol Chem 272(16):10678-10684, American Society for Biochemistry and Molecular Biology Inc., United States (Apr. 1997). [cited by applicant]
Baek, D.S., and Kim, Y.S., “Humanization of a phosphothreonine peptide-specific chicken antibody by combinatorial library optimization of the phosphoepitope-binding motif,” Biochem Biophys Res Commun 463(3):414-420, Els… [cited by applicant]
Balasingam, V., et al., “Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines,” J Neurosci 14(2):846-856, Society for Neuroscience, United States (Feb. 1994). [cited by applicant]
Benowitz, L.I., and Routtenberg, A., “GAP-43: an intrinsic determinant of neuronal development and plasticity,” Trends Neurosci 20(2):84-91, Elsevier Ltd., United Kingdom (Feb. 1997). [cited by applicant]
Better, M., et al., “ [cited by applicant]
Bird, R.E., et al., “Single-chain antigen-binding proteins,” Science 242(4877):423-426, American Association for the Advancement of Science, United States (Oct. 1988). [cited by applicant]
Bitter, G.A., et al., “Expression and secretion vectors for yeast,” Methods Enzymol 153:516-544, Academic Press Inc., United States (1987). [cited by applicant]
Boussif, O., et al., “A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine,” Proc Natl Acad Sci USA 92(16):7297-7301, National Academy of Sciences, United States (… [cited by applicant]
Brennan, M., et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United State… [cited by applicant]
Bricogne, G., “[23] Bayesian statistical viewpoint on structure determination: Basic concepts and examples,” Methods Enzymol 276:361-423, Academic Press Inc., United States (1997). [cited by applicant]
Bricogne, G., “Direct phase determination by entropy maximization and likelihood ranking: status report and perspectives,” Acta Crystallogr D Biol Crystallogr 49(Pt 1):37-60, John Wiley & Sons Inc., United States (Jan. … [cited by applicant]
Brinkman, U., et al., “Phage display of disulfide-stabilized Fv fragments,” J Immunol Methods 182(1):41-50, Elsevier, Netherlands (May 1995). [cited by applicant]
Brodeur, B.R., et al., “Mouse-Human Myeloma Partners for the Production of Heterohybridomas,” in Monoclonal Antibody Production Techniques and Applications, Schook, L.B., ed., pp. 51-63, Marcel Dekker Inc., United State… [cited by applicant]
Burton, D.R., and Barbas, C.F., “Human antibodies from combinatorial libraries,” Adv Immunol 57:191-280, Academic Press Inc., United States (1994). [cited by applicant]
Caldas, C., et al., “Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen,” Protein Eng 13(5):353-360, Oxford University Press, United Kingdom (May 2000). [cited by applicant]
Champe, M., et al., “Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a,” J Biol Chem 270(3):1388-1394, American So… [cited by applicant]
Chayen, N.E., “The role of oil in macromolecular crystallization,” Structure 5(10):1269-1274, Cell Press, United States (Oct. 1997). [cited by applicant]
Cheung, R.C., et al., “Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks,” Virology 176(2):546-552, Academic Press Inc., United States (Jun. 1990). [cited by applicant]
Chothia, C., and Lesk, A.M., “Canonical structures for the hypervariable regions of immunoglobulins,” J Mol Biol 196(4):901-917, Academic Press, United States (Aug. 1987). [cited by applicant]
Cockett, M.I., et al., “High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification,” Biotechnology (NY) 8(7):662-667, Mary Ann Liebert, U… [cited by applicant]
Colbere-Garapin, F., et al., “A new dominant hybrid selective marker for higher eukaryotic cells,” J Mol Biol 150(1):1-14, Academic Press, United States (Jul. 1981). [cited by applicant]
Couto, J.R., et al., “Anti-BA46 monoclonal antibody Mc3: humanization using a novel positional consensus and in vivo and in vitro characterization,” Cancer Res 55(8):1717-1722, American Association for Cancer Research I… [cited by applicant]
Couto, J.R., et al., “Designing human consensus antibodies with minimal positional templates,” Cancer Res 55(23 Suppl):5973s-5977s, American Association for Cancer Research Inc., United States (Dec. 1995). [cited by applicant]
Crouse, G.F., et al., “Expression and amplification of engineered mouse dihydrofolate reductase minigenes,” Mol Cell Biol 3(2):257-266, Taylor and Francis Inc., United States (Feb. 1983). [cited by applicant]
Cunningham, B.C., and Wells, J.A., “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis,” Science 244(4908):1081-1085, American Association for the Advancement of Science, United… [cited by applicant]
De Graaf, A.J., et al., “Nonnatural amino acids for site-specific protein conjugation,” Bioconjug Chem 20(7):1281-1295, American Chemical Society, United States (Jul. 2009). [cited by applicant]
Edelman, G.M., et al., “The covalent structure of an entire gammaG immunoglobulin molecule,” Proc Natl Acad Sci USA 63(1):78-85, National Academy of Sciences, United States (May 1969). [cited by applicant]
Foecking, M.K., and Hofstetter, H., “Powerful and versatile enhancer-promoter unit for mammalian expression vectors,” Gene 45(1):101-105, Elsevier B.V., Netherlands (1986). [cited by applicant]
Frese, M.A., and Dierks, T., “Formylglycine aldehyde Tag—protein engineering through a novel post-translational modification,” Chembiochem 10(3):425-427, John Wiley and Sons Inc., Germany (Feb. 2009). [cited by applicant]
Gao, Y.J., and Ji, R.R., “c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury?,” Open Pain J 2:11-17, Bentham Science Publishers B.V., N… [cited by applicant]
Gautier, A., et al., “An engineered protein tag for multiprotein labeling in living cells,” Chem Biol 15(2):128-136, American Chemical Society, United States (Feb. 2008). [cited by applicant]
Genbank, “ [cited by applicant]
Giege, R., et al., “Crystallogenesis of biological macromolecules: facts and perspectives,” Acta Crystallogr D Biol Crystallogr 50(Pt 4):339-350, John Wiley & Sons Inc., United States (Jul. 1994). [cited by applicant]
Gillies, S.D., et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes,” J Immunol Methods 125(1-2):191-202, Elsevier, Netherlands (Dec. 1989). [cited by applicant]
Glennie, M.J., et al., “Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments,” J Immunol 139(7):2367-2375, American Association of Immunologists, United State… [cited by applicant]
Goding, J.W., “Production of Monoclonal Antibodies,” in Monoclonal Antibodies: Principles and Practice, pp. 59-103, Elsevier, Netherlands (1986). [cited by applicant]
Greenspan, N.S., and Bona, C.A., “Idiotypes: structure and immunogenicity,” FASEB J 7(5):437-444, John Wiley & Sons Inc., United States (Mar. 1993). [cited by applicant]
Hackenberger, C.P.R., and Schwarzer, D., “Chemoselective ligation and modification strategies for peptides and proteins,” Angew Chem Int Ed Engl 47(52):10030-10074, Wiley-VCH, Germany (2008). [cited by applicant]
Han, J., et al., “A phosphorylation pattern-recognizing antibody specifically reacts to RNA polymerase II bound to exons,” Exp Mol Med 48(11):e271, Korean Society of Med Biochemistry and Mol Biology, South Korea (Nov. 2… [cited by applicant]
Harmsen, M.M., and De Haard, H.J., “Properties, production, and applications of camelid single-domain antibody fragments,” Appl Microbiol Biotechnol 77(1):13-22, Springer Verlag, Germany (Nov. 2007). [cited by applicant]
Herrmann, J.E., et al., “STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury,” J Neurosci 28(28):7231-7243, Society for Neuroscience, United States (Jul. 2008). [cited by applicant]
Houde, D., and Engen, J.R., “Conformational analysis of recombinant monoclonal antibodies with hydrogen/deuterium exchange mass spectrometry,” Methods Mol Biol 988:269-289, Humana Press, United States (2013). [cited by applicant]
Huston, J.S., et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Inouye, S., and Inouye, M., “Up-promoter mutations in the lpp gene of [cited by applicant]
Jefferis, R., and Lefranc, M.P., et al., “Human immunoglobulin allotypes: possible implications for immunogenicity,” Mabs 1(4):332-338, Landes Bioscience, United States (Jul.-Aug. 2009). [cited by applicant]
Ji, R.R., et al., “Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity,” Nat Neurosci 2(12):1114-1119, Nature Research, United Kingdom (Dec. 1999). [cited by applicant]
Kabat, E.A., and Wu, T.T., “Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains,” Ann NY Acad Sci 190:382-393, Wiley-Blackwell, United States (Dec. 1971). [cited by applicant]
Karpovsky, B., et al., “Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies,” J Exp Med 160(6):1686-1701, Rockefeller Unive… [cited by applicant]
Kettleborough, C.A., et al., “Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments,” Eur J Immunol… [cited by applicant]
Kilpatrick, K.E., et al., “Rapid development of affinity matured monoclonal antibodies using RIMMS,” Hybridoma 16(4):381-389, Mary Ann Liebert Inc., United States (Aug. 1997). [cited by applicant]
Kim, M., et al., “Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion,” PLoS One 7(4):e35100, Public Library of Science, United States (2012). [cited by applicant]
Kirkland, T.N., et al., “Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies,” J Immunol 137(11):3614-3619, American Association of Immunologists, United States (Dec. 1986). [cited by applicant]
Kohler, G., “Immunoglobulin chain loss in hybridoma lines,” Proc Natl Acad Sci USA 77(4):2197-2199, National Academy of Sciences, United States (Apr. 1980). [cited by applicant]
Kohler, G., and Milstein, C., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature 256(5517):495-497, Nature Research, United Kingdom (Aug. 1975). [cited by applicant]
Kosik, K.S., et al., “Human GAP-43: its deduced amino acid sequence and chromosomal localization in mouse and human,” Neuron 1(2):127-132, Cell Press, United States (Apr. 1988). [cited by applicant]
Kostelny, S.A., et al., “Formation of a bispecific antibody by the use of leucine zippers,” J Immunol 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992). [cited by applicant]
Kozbor, D., et al., “A human hybrid myeloma for production of human monoclonal antibodies,” J Immunol 133(6):3001-3005, American Association of Immunologists, United States (Dec. 1984). [cited by applicant]
Lau, C., et al., “Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation,” J Immunol 191(9):4769-4777, American Association of Immunologists, United States (Nov.… [cited by applicant]
Lee, J.Y., et al., “Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy,” Nat Commun 7:13354, Nature Publishing Group, United Kingdom (Oct. 2016). [cited by applicant]
Lee, Y., et al., “An antibody reactive to the Gly63-Lys68 epitope of NT-proBNP exhibits O-glycosylation-independent binding,” Exp Mol Med 46(9):e114, Korean Society of Med Biochemistry and Mol Biology, South Korea (Sep.… [cited by applicant]
Lefranc, M.P., et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol 27(1):55-77, Elsevier Ltd., United Kingdom (Jan. 2003). [cited by applicant]
Liu, M.A., et al., “Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes,” Proc Natl Acad Sci USA 82(24):8648-8652, National Academy of Sciences, United States (Dec. 1985). [cited by applicant]
Logan, J., and Shenk, T., “Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection,” Proc Natl Acad Sci USA 81(12):3655-3659, National Academy of Sciences, United States (Jun. 1984). [cited by applicant]
Lonberg, N., “Human antibodies from transgenic animals,” Nat Biotechnol 23(9):1117-1125, Nature Publishing Group, United Kingdom (Sep. 2005). [cited by applicant]
Lonberg, N., and Huszar, D., “Human antibodies from transgenic mice,” Int Rev Immunol 13(1):65-93, Informa Healthcare, United Kingdom (1995). [cited by applicant]
Lowy, I., et al., “Isolation of transforming DNA: cloning the hamster aprt gene,” Cell 22(3):817-823, Elsevier B.V., United States (Dec. 1980). [cited by applicant]
McCafferty, J., et al., “Phage antibodies: filamentous phage displaying antibody variable domains,” Nature 348(6301):552-554, Nature Research, United Kingdom (Dec. 1990). [cited by applicant]
McGraw, J., et al., “Modulating astrogliosis after neurotrauma,” J Neurosci Res 63(2):109-115, Wiley-Liss Inc., United States (Jan. 2001). [cited by applicant]
McPherson, A., “Crystallization of proteins from polyethylene glycol,” J Biol Chem 251(20):6300-6303, American Society for Biochemistry and Molecular Biology Inc., United States (Oct. 1976). [cited by applicant]
McPherson, A., “Current approaches to macromolecular crystallization,” Eur J Biochem 189(1):1-23, Cell Physiol Biochem Press, Switzerland (Apr. 1990). [cited by applicant]
Moldenhauer, G., et al., “Identity of HML-1 antigen on intestinal intraepithelial T cells and of B-ly7 antigen on hairy cell leukaemia,” Scand J Immunol 32(2):77-82, Wiley-Blackwell Publishing Ltd., United Kingdom (Aug.… [cited by applicant]
Morea, V., et al., “Antibody modeling: implications for engineering and design,” Methods 20(3):267-279, Academic Press Inc., United States (Mar. 2000). [cited by applicant]
Morel, G.A., et al., “Monoclonal antibodies to bovine serum albumin: affinity and specificity determinations,” Mol Immunol 25(1):7-15, Elsevier Ltd., United Kingdom (Jan. 1988). [cited by applicant]
Morgan, R.A., and Anderson, W.F., “Human gene therapy,” Annu Rev Biochem 62:191-217, Annual Reviews Inc., United States (1993). [cited by applicant]
Morrison, S.L., “Transfectomas provide novel chimeric antibodies,” Science 229(4719):1202-1207, American Association for the Advancement of Science, United States (Sep. 1985). [cited by applicant]
Mulligan, R.C., “The basic science of gene therapy,” Science 260(5110):926-932, American Association for the Advancement of Science, United States (May 1993). [cited by applicant]
Mulligan, R.C., and Berg, P., “Selection for animal cells that express the [cited by applicant]
Mullinax, R.L., et al., “Expression of a heterodimeric Fab antibody protein in one cloning step,” Biotechniques 12(6):864-869, Taylor and Francis Ltd., United Kingdom (Jun. 1992). [cited by applicant]
Muyldermans, S., “Single domain camel antibodies: current status,” J Biotechnol 74(4):277-302, Elsevier B.V., Netherlands (Jun. 2001). [cited by applicant]
Nabel, G.J., and Felgner, P.L., “Direct gene transfer for immunotherapy and immunization,” Trends Biotechnol 11(5):211-215, Elsevier Ltd., United Kingdom (May 1993). [cited by applicant]
Naganawa, Y., et al., “Generation of mouse-human hybridomas secreting human monoclonal antibodies to Japanese cedar pollen allergen Cry j1,” Hum Antibodies 14(1-2):27-31, IOS Press BV, Netherlands (2005). [cited by applicant]
Ng, S.C., et al., “Cloning of human GAP-43: growth association and ischemic resurgence,” Neuron 1(2):133-139, Cell Press, United States (Apr. 1988). [cited by applicant]
Nisonoff, A., “Idiotypes: concepts and applications,” J Immunol 147(8):2429-2438, American Association of Immunologists, United States (Oct. 1991). [cited by applicant]
Nuttall, S.D., et al., “Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents,” Curr Pharm Biotechnol 1(3):253-263, Bentham Science Publishers B.V., Netherlands (Nov.… [cited by applicant]
O'Hare, K., et al., “Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase,” Proc Natl Acad Sci USA 78(3):1527-1531, National Academy of… [cited by applicant]
Oi, V.T., and Morrison, S.L., “Chimeric Antibodies,” Biotechniques 4(3):214-221, Taylor and Francis Ltd., United Kingdom (1986). [cited by applicant]
Padlan, E.A., “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties,” Mol Immunol 28(4-5):489-498, Elsevier Ltd., United Kingdom (Apr.-May 19… [cited by applicant]
Paulus, H., “Preparation and biomedical applications of bispecific antibodies,” Behring Inst Mit 78:118-132, Behringwerke AG, Germany (Dec. 1985). [cited by applicant]
Pedersen, J.T., et al., “Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies,” J Mol Biol 235(3):959-973, Academic Press, United Sta… [cited by applicant]
Persic, L., et al., “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries,” Gene 187(1):9-18, Elsevier, Netherlands (Mar. 1997). [cited by applicant]
Proudfoot, N.J., “Transcriptional interference and termination between duplicated alpha-globin gene constructs suggests a novel mechanism for gene regulation,” Nature 322(6079):562-565, Nature Research, United Kingdom (… [cited by applicant]
Ren, H., et al., “A biocompatible condensation reaction for the labeling of terminal cysteine residues on proteins,” Angew Chem Int Ed Engl 48(51):9658-9662, Wiley-VCH, Germany (2009). [cited by applicant]
Rhodes, K.E., and Fawcett, J.W., “Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS?,” J Anat 204(1):33-48, Wiley-Blackwell Publishing Ltd., United Kingdom (Jan. 2004). [cited by applicant]
Riechmann, L., and Muyldermans, S., “Single domain antibodies: comparison of camel VH and camelised human VH domains,” J Immunol Methods 231(1-2):25-38, Elsevier B.V., Netherlands (Dec. 1999). [cited by applicant]
Roguska, M.A., et al., “A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing,” Protein Eng 9(10):895-904, Oxford University Press, United Kingdom (Oct. 1996). [cited by applicant]
Roguska, M.A., et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,” Proc Natl Acad Sci USA 91(3):969-973, National Academy of Sciences, United States (Feb. 1994). [cited by applicant]
Roux, K.H., et al., “Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry,” J Immunol 161(8):4083-4090, American Association of … [cited by applicant]
Ruther, U., and Muller-Hill, B., “Easy identification of cDNA clones,” EMBO J 2(10):1791-1794, Springer Nature, Germany (1983). [cited by applicant]
Sandhu, J.S., “A rapid procedure for the humanization of monoclonal antibodies,” Gene 150(2):409-410, Elsevier B.V., Netherlands (Dec. 1994). [cited by applicant]
Santerre, R.F., et al., “Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells,” Gene 30(1-3):147-156, Elsevier B.V., Netherlands (Oct. 1984). [cited by applicant]
Senter, P.D., “Potent antibody drug conjugates for cancer therapy,” Curr Opin Chem Biol 13(3):235-244, Elsevier Ltd., United Kingdom (Jun. 2009). [cited by applicant]
Shinmoto, H., et al., “Generation of mouse-human hybridomas secreting antibodies against peanut allergen Ara h1,” Cytotechnology 46(1):19-23, Springer Netherlands, Netherlands (Sep. 2004). [cited by applicant]
Sofroniew, M.V., “Molecular dissection of reactive astrogliosis and glial scar formation,” Trends Neurosci 32(12):638-647, Elsevier Ltd. United Kingdom (Dec. 2009). [cited by applicant]
Sofroniew, M.V., “Reactive astrocytes in neural repair and protection,” Neuroscientist 11(5):400-407, SAGE Publications Inc., United States (Oct. 2005). [cited by applicant]
Songsivilai, S., and Lachman, P.J., “Bispecific antibody: a tool for diagnosis and treatment of disease,” Clin Exp Immunol 79(3):315-321, Oxford University Press, United Kingdom (Mar. 1990). [cited by applicant]
Sormanni, P., et al., “Rapid and accurate in silico solubility screening of a monoclonal antibody library,” Sci Rep 7(1):8200, Nature Publishing Group, United Kingdom (Aug. 2017). [cited by applicant]
Stahli, C., et al., “Distinction of epitopes by monoclonal antibodies,” Methods Enzymol 92:242-253, Academic Press Inc., United States (1983). [cited by applicant]
Studnicka, G.M., et al., “Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues,” Protein Eng 7(6):805-814, Oxford University Press, Unite… [cited by applicant]
Sunbul, M., and Yin, J., “Site specific protein labeling by enzymatic posttranslational modification,” Org Biomol Chem 7(17):3361-3371, Royal Society of Chemistry, United Kingdom (Sep. 2009). [cited by applicant]
Szybalska, E.H., and Szybalski, W., “Genetics of human cell line. IV. DNA-mediated heritable transformation of a biochemical trait,” Proc Natl Acad Sci USA 48(12):2026-2034, National Academy of Sciences, United States (… [cited by applicant]
Taki, M., et al., “Transglutaminase-mediated N- and C-terminal fluorescein labeling of a protein can support the native activity of the modified protein,” Protein Eng Des Sel 17(2):119-126, Oxford University Press, Unit… [cited by applicant]
Tan, P., et al., ““Superhumanized” antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28,” J Immunol 169(2):1119-1125, A… [cited by applicant]
Tang, T.Y., et al., “TAFA: a novel secreted family with conserved cysteine residues and restricted expression in the brain,” Genomics 83(4):727-734, Academic Press, United States (Apr. 2004). [cited by applicant]
Taylor, E.V., and Imperiali, B., “Native Chemical Ligation: SemiSynthesis of Post-translationally Modified Proteins and Biological Probes,” Protein Engineering 22:65-96, Oxford University Press, United Kingdom (2009). [cited by applicant]
Tolstoshev, P., “Gene therapy, concepts, current trials and future directions,” Annu Rev Pharmacol Toxicol 33:573-596, Annual Reviews Inc., United States (1993). [cited by applicant]
Van Heeke, G., and Schuster, S.M., “Expression of human asparagine synthetase in [cited by applicant]
Vidarsson, G., et al., “IgG subclasses and allotypes: from structure to effector functions,” Front Immunol 5:520, Frontiers Media SA, Switzerland (Oct. 2014). [cited by applicant]
Ward, E.S., et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Wigler, M., et al., “Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells,” Cell 11(1):223-232, Elsevier B.V., United States (May 1977). [cited by applicant]
Wigler, M., et al., “Transformation of mammalian cells with an amplifiable dominant-acting gene,” Proc Natl Acad Sci USA 77(6):3567-3570, National Academy of Sciences, United States (Jun. 1980). [cited by applicant]
Winter, C.G., et al., “A role for ciliary neurotrophic factor as an inducer of reactive gliosis, the glial response to central nervous system injury,” Proc Natl Acad Sci USA 92(13):5865-5869, National Academy of Science… [cited by applicant]
Wu, G.Y., and Wu, C.H., “Delivery systems for gene therapy,” Biotherapy 3(1):87-95, Springer International Publishing AG, Switzerland (1991). [cited by applicant]
Yoon, A., et al., “Chicken scFvs with an Artificial Cysteine for Site-Directed Conjugation,” PLoS One 11(1):e0146907, Public Library of Science, United States (Jan. 2016). [cited by applicant]
Boussif, O., et al., “A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine,” Proceedings of the National Academy of Sciences of the United States of America 92(16)… [cited by applicant]
Han, Jungwon, et al., “A phosphorylation pattern-recognizing antibody specifically reacts to RNA polymerase II bound to exons,” Experimental & Molecular Medicine 48(11): e271-e271, Nature Publishing, United Kingdom (Nov… [cited by applicant]
Houde, D., et al., “Conformational analysis of recombinant monoclonal antibodies with hydrogen/deuterium exchange mass spectrometry,” Methods Mol Bio 988:269-289, SpringerLink, United States (Dec. 2013). [cited by applicant]
International Search Report and Written Opinion mailed May 1, 2020 in International Application No. PCT/IB2019/061461, KIPO, Korea, 12 pages. [cited by applicant]
Kim, M., et al., “Gremlin-1 Induces BMP-Independent Tumor Cell Proliferation, Migration, and Invasion,” PLoS One 7(4):e35100, Public Library of Science, United States (Apr. 2012). [cited by applicant]
Korea University, “Discovery and functional characterization of novel peptidome,” Brain Science Source Technology Development Project Final Report, 1-46, Korea (Nov. 2017). [cited by applicant]
Lee, Y., et al., “An antibody reactive to the Gly [cited by applicant]
Sormanni, P., et al., “Rapid and accurate in silico solubility screening of a monoclonal antibody library,” Sci Rep 7(1): 8200, Nature Publishing Group, England (Aug. 2017). [cited by applicant]
Wang, Y., et al., “Novel adipoline, FAM19A5, inhibits neointima formation after injury through sphingosine-1-phosphate receptor 2,” Circulation 138:48-63, American Heart Association, United States (Jul. 2018). [cited by applicant]
U.S. Appl. No. 19/054,436, inventors Kim, B., et al., filed Feb. 14, 2025 (Not yet Published). [cited by applicant]
Bordusa, F., “Protease-catalyzed Formation of C—N Bonds,” Highlights in Bioorganic Chemistry 389-403, Wiley-VCH, Germany (Jan. 2004). [cited by applicant]
Tian, F., et al., “A general approach to site-specific antibody drug conjugates,” Proc Natl Acad Sci USA, 111(5):1766-71, United States (Feb. 2014). [cited by applicant]
Hammerling, G.J., et al., “Appendix: Production of Antibody-Producing Hybridomas in the RodentSystems,” in: Monoclonal Antibodies and T-Cell Hybridomas: Perspectives and Technical Advances, pp. 563-587, Elsevier, Nether… [cited by applicant]
Harlow, E., and Lane, D., “Epitope Mapping by Competition Assay,” CSH protocol, Cold Spring Harbor Laboratory, United States (2006). [cited by applicant]
Roversi, P., et al., “Modelling Prior Distributions of Atoms for Macromolecular Refinement and Completion,” Acta Crystallographica. Section D, Biological Crystallography 56(Pt10):1316-1323, Wiley-Blackwell, United State… [cited by applicant]
Sawai, H., et al., “Direct Production of the Fab Fragment Derived From the Sperm Immobilizing Antibody Using Polymerase Chain Reaction and cDNA Expression Vectors,” American Journal of reproductive immunology 34(1):26-3… [cited by applicant]
UniProt, “Neum Human,” Accession No. P17677, accessed at https://www.uniprot.org/uniprotkb/P17677/entry, accessed on Jun. 13, 2025, 10 pages. [cited by applicant]
UniProt, “TAFA5_HUMAN,” Accession No. Q7Z5A7, accessed at https://www.uniprot.org/uniprotkb/Q775A7/entry, accessed on Jun. 13, 2025, 9 pages. [cited by applicant]
Chen, C., et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” EMBO J 14(12):2784-94, Springer, United Kingdom (Jun. 1995… [cited by applicant]
Colman, P.M., “Effects of amino acid sequence changes on antibody-antigen interactions,” Res Immunol 145(1):33-6, Elsevier, Netherlands (Jan. 1994). [cited by applicant]
Foote, J., et al., “Antibody framework residues affecting the conformation of the hypervariable loops,” J Mol Biol 224(2):487-99, Elsevier, Netherlands (Mar. 1992). [cited by applicant]
Winter, G., et al., “Humanized antibodies,” Immunol Today 14(6):243-6, Elsevier, Netherlands (Jun. 1993). [cited by applicant]